The OCT1 activity was reported to correlate with the sensitivity of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML) (79). The gene discussed is SLC22A1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.